Roche presents detailed ocrelizumab data

Roche (SIX:ROG; OTCQX:RHHBY) announced data from two Phase III studies of ocrelizumab ( RG1594) showing superiority to Rebif interferon beta-1a from Merck KGaA (Xetra:MRK) to treat relapsing multiple sclerosis. The company also announced data from a third Phase III study showing ocrelizumab reduced the risk of disease progression in patients with primary progressive MS (PPMS).

Roche had already announced top-line results from the three studies. Data are to be presented at this week's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona (see BioCentury Extra, June 30 and Sept. 28). ...